154 related articles for article (PubMed ID: 12698670)
21. Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure.
Burger AJ; Aronson D
J Card Fail; 2001 Jun; 7(2):122-8. PubMed ID: 11420763
[TBL] [Abstract][Full Text] [Related]
22. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.
Cheng V; Kazanagra R; Garcia A; Lenert L; Krishnaswamy P; Gardetto N; Clopton P; Maisel A
J Am Coll Cardiol; 2001 Feb; 37(2):386-91. PubMed ID: 11216951
[TBL] [Abstract][Full Text] [Related]
23. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
Silver MA; Horton DP; Ghali JK; Elkayam U
J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
[TBL] [Abstract][Full Text] [Related]
24. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
[TBL] [Abstract][Full Text] [Related]
25. Neurohormonal determinants of peak oxygen uptake in patients with chronic heart failure.
Kinugawa T; Kato M; Ogino K; Igawa O; Hisatome I; Shigemasa C; Nohara R
Jpn Heart J; 2003 Sep; 44(5):725-34. PubMed ID: 14587654
[TBL] [Abstract][Full Text] [Related]
26. Nesiritide: a review of its use in acute decompensated heart failure.
Keating GM; Goa KL
Drugs; 2003; 63(1):47-70. PubMed ID: 12487622
[TBL] [Abstract][Full Text] [Related]
27. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.
Tsutamoto T; Hisanaga T; Wada A; Maeda K; Ohnishi M; Fukai D; Mabuchi N; Sawaki M; Kinoshita M
J Am Coll Cardiol; 1998 Feb; 31(2):391-8. PubMed ID: 9462584
[TBL] [Abstract][Full Text] [Related]
29. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.
Berger R; Huelsman M; Strecker K; Bojic A; Moser P; Stanek B; Pacher R
Circulation; 2002 May; 105(20):2392-7. PubMed ID: 12021226
[TBL] [Abstract][Full Text] [Related]
30. Cardiac troponin I and ventricular arrhythmia in patients with chronic heart failure.
Liu Z; Cui L; Wang Y; Guo Y
Eur J Clin Invest; 2006 Jul; 36(7):466-72. PubMed ID: 16796603
[TBL] [Abstract][Full Text] [Related]
31. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure.
Burger AJ; Aronson D
Int J Cardiol; 2001 Dec; 81(2-3):243-9. PubMed ID: 11744142
[TBL] [Abstract][Full Text] [Related]
32. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium.
Oladapo OO; Falase AO
Afr J Med Med Sci; 2000; 29(3-4):265-8. PubMed ID: 11714003
[TBL] [Abstract][Full Text] [Related]
33. Dispersion of QT interval in premature ventricular beats as a marker of susceptibility to arrhythmic events.
Dabrowski A; Kramarz E; Piotrowicz R
J Cardiovasc Risk; 1998 Apr; 5(2):97-101. PubMed ID: 9821062
[TBL] [Abstract][Full Text] [Related]
34. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.
Maeda K; Tsutamoto T; Wada A; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Kinoshita M
J Am Coll Cardiol; 2000 Nov; 36(5):1587-93. PubMed ID: 11079662
[TBL] [Abstract][Full Text] [Related]
35. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators.
Benedict CR; Johnstone DE; Weiner DH; Bourassa MG; Bittner V; Kay R; Kirlin P; Greenberg B; Kohn RM; Nicklas JM
J Am Coll Cardiol; 1994 May; 23(6):1410-20. PubMed ID: 7909822
[TBL] [Abstract][Full Text] [Related]
36. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure.
Ogawa M; Zhou S; Tan AY; Song J; Gholmieh G; Fishbein MC; Luo H; Siegel RJ; Karagueuzian HS; Chen LS; Lin SF; Chen PS
J Am Coll Cardiol; 2007 Jul; 50(4):335-43. PubMed ID: 17659201
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
Koller-Strametz J; Pacher R; Frey B; Kos T; Woloszczuk W; Stanek B
J Heart Lung Transplant; 1998 Apr; 17(4):356-62. PubMed ID: 9588580
[TBL] [Abstract][Full Text] [Related]
38. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
de Lissovoy G; Stier DM; Ciesla G; Munger M; Burger AJ
Am J Cardiol; 2003 Sep; 92(5):631-3. PubMed ID: 12943895
[TBL] [Abstract][Full Text] [Related]
39. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure.
Aronson D; Burger AJ
Am J Cardiol; 2002 Aug; 90(4):435-8. PubMed ID: 12161240
[No Abstract] [Full Text] [Related]
40. Long-term treatment of congestive heart failure with oral ibopamine. Effects of rhythm disorders and neurohormonal alterations.
Caponnetto S; Terrachini V; Canale C; Bruzzone F; Masperone MA; Pastorino L; Licciardello L; Marchetti GV
Cardiology; 1990; 77 Suppl 5():43-8. PubMed ID: 1980633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
